Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

Gadan, Mario Alberto; González, S.J.; Batalla, M.; Olivera, María Silvina; Policastro, L.; Sztejnberg, Manuel

doi:10.1016/j.apradiso.2015.07.006

Cited by 10 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been few studies to date investigating the use of BNCT in breast malignancies, although BNCT may have a role as a potential option for treating HER2 overexpressing breast cancers based on promising pre-clinical data. Immunoliposomes, such as those labeled with trastuzumab, have been proposed to act as a boron carrier and can selectively target HER2 overexpressing cells (67). Further, dosimetric analyses have shown the possibility of BNCT for locally recurrent breast cancer (68).…”

Section: Breast Cancersmentioning

confidence: 99%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget’s disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.

show abstract

Section: Breast Cancersmentioning

confidence: 99%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This finding is in agreement with a previous finding that PGB-0 exhibits cytotoxic activity in HER2-positive breast cancer cells. [ 5 7 14 ] Our compound also interacted with an essential nuclear factor kappa B related protein, IKK,[ 15 ] with an analogous docking score to its native ligand. Recent studies have explored various FR[ 16 ] and integrin αvβ3-targeted cancer therapies[ 17 ] including BNCT.…”

Section: Discussionmentioning

confidence: 99%

Synthesis and cytotoxicity of the boron carrier pentagamaboronon-0-ol for boron neutron capture therapy against breast cancer

Utomo

Wulandari

Novitasari

et al. 2022

Journal of Advanced Pharmaceutical Technology &Amp; Research

View full text Add to dashboard Cite

Boronic acid-containing curcumin analog, pentagamaboronon-0 (PGB-0), acts as a potential boron-carrier agent but has limited water solubility. Thus, a new compound (PGB-0-ol) with better chemical and pharmacological properties than PGB-0 has been synthesized. Molecular docking was performed using a molecular operating environment. Prediction of PGB-0-ol absorption, distribution, metabolism, and excretion (ADME) was performed using pkCSM software. PGB-0-ol was synthesized by adding NaBH4 to PGB-0 and stirring for 1 h. The crude PGB-0-ol was purified using preparative layer chromatography. Cell viability was evaluated using the trypan blue exclusion assay. In comparison to PGB-0 based on molecular docking study, PGB-0-ol could interact in with several cancer biomarkers, such as human epidermal growth factor2 epidermal growth factor receptor, IκB kinase, folate receptor-α, and integrin αvβ3. PGB-0-ol also showed an improved ADME profile because of its higher water solubility than PGB-0. PGB-0-ol was synthesized by selective ketone reduction of PGB-0 into primary alcohol by sodium borohydrate producing 30% yield. The cytotoxicity of PGB-0-ol against several breast cancer cells was lower than that of PGB-0. The novel compound PGB-0-ol was synthesized using simple steps. PGB-0-ol has low cytotoxicity against breast cancer cells and could be applied in boron neutron capture therapy as a boron carrier.

show abstract

“…In the frame of the Argentinean Boron Neutron Capture Therapy Project at the National Atomic Energy Commission (CNEA), a research line, aimed to study the feasibility of applying BNCT to the treatment of locoregional recurrences of the HER-2 breast cancer subtype, is under development (Gadan et al, 2015). The strategy considers the design and use of immunoliposomes as boron carrier nanovehicles to target HER-2-overexpressing cells as a paradigm case study.…”

Section: Discussionmentioning

confidence: 99%

Neutron Autoradiography Combined With UV-C Sensitization: Toward the Intracellular Localization of Boron

et al. 2019

View full text Add to dashboard Cite

Our group has reported the imprint formation of biological material on polycarbonate nuclear track detectors by UV-C exposure, which is used as an approach to simultaneously visualize cell imprints and nuclear tracks coming from the boron neutron capture reaction. Considering that the cell nucleus has a higher UV-C absorption than the cytoplasm and that hematoxylin preferentially stains the nucleus, we proposed to enhance the contrast between these two main cell structures by hematoxylin staining before UV-C sensitization. In this study, several experiments were performed in order to optimize UV-C exposure parameters and chemical etching conditions for cell imprint formation using the SK-BR-3 breast cancer cell line. The proposed method improves significantly the resolution of the cell imprints. It allows clear differentiation of the nucleus from the rest of the cell, together with nuclear tracks pits. Moreover, it reduces considerably the UV-C exposure time, an important experimental issue. The proposed methodology can be applied to study the boron distribution independently from the chosen cell line and/or boron compounds.

show abstract

Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

Cited by 10 publications

References 19 publications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Synthesis and cytotoxicity of the boron carrier pentagamaboronon-0-ol for boron neutron capture therapy against breast cancer

Neutron Autoradiography Combined With UV-C Sensitization: Toward the Intracellular Localization of Boron

Contact Info

Product

Resources

About